文献速递神经肿瘤

TERT启动子甲基化与垂体腺瘤中TERT上调及疾病进展显著相关

TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.
PubMed 文献 · J Neurooncol · 2018-11-03

该回顾性研究纳入70例垂体腺瘤(53例原发、17例复发),采用Sanger测序检测TERT启动子热点突变、MS-HRM定量甲基化、实时定量PCR检测TERT mRNA。未发现TERT启动子热点突变,16%的垂体腺瘤存在TERT启动子甲基化。甲基化组疾病进展更常见、无进展生存期更短、TERT表达更高。

要点

  • 70例垂体腺瘤中未检测到TERT启动子热点突变
  • 16%的垂体腺瘤存在TERT启动子甲基化
  • 甲基化组疾病进展更常见、无进展生存期更短、TERT表达更高

核心结论

  • 首次显示垂体腺瘤中TERT启动子甲基化与疾病进展、较短无进展生存期及TERT表达上调相关。
  • 结果提示TERT启动子甲基化可能是预测垂体腺瘤肿瘤复发的潜在生物标志物。

研究设计与样本

  • 回顾性研究纳入70例垂体腺瘤,包括53例原发样本和17例复发样本。
  • 从病历获取手术时年龄、性别、肿瘤最大径、肿瘤亚型、切除率及无进展生存期(PFS)等临床资料。
  • 采用Sanger测序检测TERT启动子热点突变,采用甲基化敏感高分辨率熔解分析(MS-HRM)定量TERT启动子甲基化状态,采用实时定量PCR检测TERT mRNA表达。

主要发现

  • 任何垂体腺瘤样本中均未观察到TERT启动子热点突变。
  • 16%的垂体腺瘤显示TERT启动子甲基化。
  • 与TERT启动子未甲基化的垂体腺瘤相比,TERT启动子甲基化的垂体腺瘤显著更常见疾病进展、无进展生存期更短、TERT表达水平更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Alterations in the promoter of the telomerase reverse transcriptase (TERT) gene are a major mechanism of upregulating telomerase, which plays a crucial role in tumor development. Mutations in the TERT promoter have been observed in a subset of brain tumors, including adult gliomas and high-grade meningiomas. In pituitary adenomas (PAs), however, abnormalities in TERT are not fully understood. The present study aimed to investigate not only mutational but also methylation changes in the TERT promoter in PAs and to analyze their correlations with clinical variables. METHODS: We retrospectively studied 70 PAs consisting of 53 primary and 17 recurrent samples. Clinical data, including age at surgery, sex, largest tumor dimension, tumor subtype, resection rate, and progression-free survival (PFS), were obtained from medical records. We investigated TERT promoter hotspot mutations via Sanger sequencing and quantified the methylation status of the TERT promoter using methylation-sensitive high-resolution melting analysis (MS-HRM). Additionally, we investigated TERT mRNA expression using real-time quantitative PCR. RESULTS: TERT promoter hotspot mutations were not observed in any PA sample, while 16% of PAs exhibited TERT promoter methylation. PAs with methylated TERT promoters were significantly more likely to show disease progression, shorter PFS, and higher TERT expression levels compared to those with unmethylated promoters. CONCLUSIONS: This is the first study showing that TERT promoter methylation is associated with disease progression and shorter PFS as well as upregulated TERT expression in PAs. Our results suggest that TERT promoter methylation may be a potential biomarker for predicting tumor recurrence in PAs.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Miyake Y, Adachi JI, Suzuki T, et al. TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas. J Neurooncol. 2018. PMID: 30392088. doi:10.1007/s11060-018-03016-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。